Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Bioanalysis

• Publication date

  2010-03-16

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.4155/bio.10.6PMID 21083253
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Value of Improving the Productivity of the Drug Development Process

  2012cited by this paper
• Anti-Human Immunodeficiency Virus Activity, Cross-Resistance, Cytotoxicity, and Intracellular Pharmacology of the 3′-Azido-2′,3′-Dideoxypurine Nucleosides

  2009cited by this paper
• A pharmacokinetic evaluation of five H(1) antagonists after an oral and intravenous microdose to human subjects.

  2009cited by this paper
• The utility of microdosing over the past 5 years

  2008cited by this paper
• Use of accelerator mass spectrometry to measure the pharmacokinetics and peripheral blood mononuclear cell concentrations of zidovudine.

  2008cited by this paper
• Commentary on ACCP Position Statement on the Use of Microdosing in the Drug Development Process

  2007cited by this paper
• American College of Clinical Pharmacology Position Statement on the Use of Microdosing in the Drug Development Process

  2007cited by this paper
• What common structural features and variations of mammalian P450s are known to date?

  2007cited by this paper
• Nontraditional approaches to first‐in‐human studies to increase efficiency of drug development: will microdose studies make a significant impact?

  2007cited by this paper
• Pharmacogenetics of warfarin: current status and future challenges

  2007cited by this paper
• Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction

  2006cited by this paper
• Use of microdosing to predict pharmacokinetics at the therapeutic dose: Experience with 5 drugs

  2006cited by this paper
• How many genomics targets can a portfolio afford?

  2005cited by this paper
• Can the pharmaceutical industry reduce attrition rates?

  2004cited by this paper
• Environmental and chemical carcinogenesis.

  2004cited by this paper
• R&D Costs and Returns by Therapeutic Category

  2004cited by this paper
• Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans

  2004cited by this paper
• The formation of AFB(1)-macromolecular adducts in rats and humans at dietary levels of exposure.

  2004cited by this paper
• The price of innovation: new estimates of drug development costs.

  2003cited by this paper
• ADMET in silico modelling: towards prediction paradise?

  2003cited by this paper
• A guide to drug discovery: Making Better Drugs: Decision Gates in Non-Clinical Drug Development

  2003cited by this paper
• Big physics, small doses: the use of AMS and PET in human microdosing of development drugs

  2003cited by this paper
• Physiologically-based pharmacokinetic simulation modelling.

  2002cited by this paper
• The druggable genome

  2002cited by this paper
• General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition

  2001cited by this paper
• Pushing the accelerator – speeding up drug research with accelerator mass spectrometry

  2000cited by this paper
• Microarrays and toxicology: The advent of toxicogenomics

  1999cited by this paper
• Comparison of DNA‐adduct and tissue‐available dose levels of MeIQx in human and rodent colon following administration of a very low dose

  1999cited by this paper
• MeIQx-DNA adduct formation in rodent and human tissues at low doses.

  1997cited by this paper

• Atom counting with accelerator mass spectroscopy

  2023cites this paper
• Stable Isotopically Labeled Intravenous Microdose Pharmacokinetic Trials as a Tool to Assess Absolute Bioavailability: Feasibility and Paradigm to Apply for Protein Kinase Inhibitors in Oncology

  2020cites this paper
• Combining Isotopic Tracer Techniques to Increase Efficiency of Clinical Pharmacokinetic Trials in Oncology

  2020cites this paper
• Oxaliplatin–DNA Adducts as Predictive Biomarkers of FOLFOX Response in Colorectal Cancer: A Potential Treatment Optimization Strategy

  2020cites this paper
• Phase 0/microdosing approaches: time for mainstream application in drug development?

  2020cites this paper
• Phase 0/microdosing approaches: time for mainstream application in drug development?

  2020cites this paper
• Absorption, distribution, metabolism and excretion of an isocitrate dehydrogenase-2 inhibitor enasidenib in rats and humans

  2019cites this paper
• Absorption, distribution, metabolism, and excretion of mTOR kinase inhibitor CC-223 in rats, dogs, and humans

  2019cites this paper
• Microdosing strategy on human pharmacokinetics , metabolism and drug development

  2018cites this paper
• Applications of 14 C, the Most Versatile Radionuclide to Explore Our World

  2018cites this paper
• A diagnostic microdosing approach to investigate platinum sensitivity in non‐small cell lung cancer

  2017cites this paper
• A double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]-basimglurant and absolute bioavailability after oral administration and concomitant intravenous microdose administration of [13C6]-labeled basimglurant in humans

  2017cites this paper
• Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients

  2017cites this paper
• Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients

  2017cites this paper
• Opportunities to Apply the 3Rs in Safety Assessment Programs

  2016cites this paper
• Use of Accelerator Mass Spectrometry in Human Health and Molecular Toxicology.

  2016cites this paper
• Regulatory aspects of human radiolabeled mass balance studies in oncology: concise review

  2016cites this paper
• Accelerator mass spectrometry: state of the art and perspectives

  2016cites this paper
• IN VITRO METHODS FOR EVALUATION OF DRUG METABOLISM

  2016cites this paper
• Chapter 4.3 – Exploratory Clinical Studies (“Phase 0 Trials”)

  2015cites this paper
• Observational infant exploratory [(14)C]-paracetamol pharmacokinetic microdose/therapeutic dose study with accelerator mass spectrometry bioanalysis.

  2015cites this paper
• Microdosing: An Emerging Tool for Drug Development

  2015cites this paper
• Human-based Systems in Drug and Chemical Safety Testing — toward Replacement, the ‘Single R’

  2014cites this paper
• Dose-dependent exposure and metabolism of GNE-892, a β-secretase inhibitor, in monkeys: contributions by P450, AO, and P-gp

  2014cites this paper
• Quantitation of Drug Metabolites by Radioactivity Detection Including Accelerator Mass Spectrometry (AMS)

  2014cites this paper
• The debate on animal ADME studies in drug development: an update

  2014cites this paper
• Disposition and Metabolic Profiling of [14C]Cerlapirdine Using Accelerator Mass Spectrometry

  2014cites this paper
• Iodine-129 microdosing for protein and peptide drug development: erythropoietin as a case study.

  2013cites this paper
• Applications of accelerator mass spectrometry

  2013cites this paper
• High-sensitive LC-MS/MS method for the simultaneous determination of mirodenafil and its major metabolite, SK-3541, in human plasma: application to microdose clinical trials of mirodenafil.

  2013cites this paper
• Selected scientific topics of the 11th International Isotope Symposium on the Synthesis and Applications of Isotopes and Isotopically Labeled Compounds.

  2013cites this paper
• AFN-1252 in vitro absorption studies and pharmacokinetics following microdosing in healthy subjects.

  2013cites this paper
• Microdosing Assessment to Evaluate Pharmacokinetics and Drug Metabolism Using Liquid Chromatography-Tandem Mass Spectrometry Technology

  2012cites this paper
• Ultrasensitive liquid chromatography-tandem mass spectrometric methodologies for quantification of five HIV-1 integrase inhibitors in plasma for a microdose clinical trial.

  2012cites this paper
• PHARMACO-ECONOMICS OF MICRODOSING CLINICAL TRIALS IN DRUG DEVELOPMENT PROCESS

  2012cites this paper
• Topics on Drug Metabolism

  2012cites this paper
• Quantifying exploratory low dose compounds in humans with AMS.

  2011cites this paper
• Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers.

  2011cites this paper
• Bioanalytical aspects of clinical mass balance studies in oncology.

  2011cites this paper